The EZH2 selective inhibitor ZLD1039 attenuates UUO-induced renal fibrosis by suppressing YAP activation
Abstract Renal fibrosis is a manifestation of the progression of chronic kidney disease (CKD) and chronic inflammation is a main driver in the development of renal fibrosis. Yes-associated protein (YAP), acting as a transcriptional co-activator within the Hippo signaling pathway, has been implicated...
Saved in:
| Main Authors: | Qingling Xia, Fujiang Xu, Lidan Zhang, Wenfei Ding, Jiang Liu, Jing Liu, Minhao Chen, Santao Ou, Yong Xu, Li Wen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Molecular Biomedicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43556-025-00276-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research progress of EZH2 in non-tumor renal diseases
by: Wang Hui, et al.
Published: (2025-05-01) -
GGCT participates in the malignant process of hepatocellular cancer cells by regulating the PTEN/PI3K/AKT pathway through binding to EZH2
by: Junbo He, et al.
Published: (2025-02-01) -
Non-steroidal mineralocorticoid receptor antagonist finerenone inhibits peritoneal fibrosis induced by high-glucose dialysate via regulating enhancer of zeste homolog 2 (EZH2) expression
by: Dandan Chen, et al.
Published: (2025-12-01) -
miR‐4448/Girdin/Akt/AMPK axis inhibits EZH2‐mediated EMT and tumorigenesis in small‐cell lung cancer
by: Nobuyuki Koyama, et al.
Published: (2024-10-01) -
Expression and clinical significance of FGL1 and YAP1 in colorectal cancer
by: LIU Yuanming*,CUI Guangjie,CHEN Jiaqi,LU Yang,GAO Chao
Published: (2025-07-01)